The Latest Breaking News from Merck

The pharmaceutical industry is set for long-term growth due to growing demand for quality drugs and therapies, an aging population, and the rise in lifestyle-related diseases. Now, let's explore the investment potential of industry giants Merck & Co (MRK), Johnson & Johnson (JNJ), and AbbVie (ABBV). Keep reading.

Plus: Frazier talks about the shareholders who trusted his vision enough to support him in his early days at the helm.

Despite at least nine lawsuits against the government, all companies whose drugs are up for Medicare price negotiation will come to the bargaining table.

In a politicized world, the former Merck boss says CEOs should stand up and speak out. “Pick your spots.”

Yesterday, with Merck trading at $103.94, the November put option with a strike price of $100 was trading around $1.78. Traders selling this put would receive $178 in option premium.

Minnesota senator and anti-monopoly crusader explains how fixing Medicare's drug problem will help everybody

Just over half of hiring managers say removing four-year degree requirements would positively impact their company's hiring practices, according to a OneTen report.

Government claims prices could fall for 9m seniors but pharma companies claim cost-reduction program is unconstitutional

The move is expected to cut costs in a few years for some patients but faces litigation from the drugmakers and heavy criticism from Republican lawmakers.